HRP20200894T1 - Novi antibakterijski spojevi - Google Patents
Novi antibakterijski spojevi Download PDFInfo
- Publication number
- HRP20200894T1 HRP20200894T1 HRP20200894TT HRP20200894T HRP20200894T1 HR P20200894 T1 HRP20200894 T1 HR P20200894T1 HR P20200894T T HRP20200894T T HR P20200894TT HR P20200894 T HRP20200894 T HR P20200894T HR P20200894 T1 HRP20200894 T1 HR P20200894T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- alkylenyl
- image
- infection
- bond
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 17
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000004672 Cardiovascular Infections Diseases 0.000 claims 1
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 1
- 206010061977 Genital infection female Diseases 0.000 claims 1
- 206010065764 Mucosal infection Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- -1 azabicyclooctyl Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (15)
1. Spoj, naznačen time, da je predstavljen sljedećom formulom (1):
A-L1-Y-L2-R-B (1)
u kojoj
A je ciklička skupina koja ima sljedeću formulu (II):
[image]
gdje
G3 je CH ili N, kada crtkana linija predstavlja dvostruku vezu, ili je CH2, NH ili O, kada crtkana linija predstavlja jednostruku vezu;
C1 predstavlja atome koji su potrebni za tvorbu alifatskog ili aromatskog šesteročlanog prstena koji izborno sadrži jedan ili više heteroatoma odabranih od atoma dušika i atoma kisika, dok je navedeni prsten izborno supstituiran s jednim ili više supstituenata koji su odabrani iz skupine koja se sastoji od atoma halogena, (C1-3)alkil-skupine, cijano-skupine, okso-skupine (=O) i (C1-3)alkoksi-skupine;
L1 je δ-veza ili (C1-3)alkilenil-skupina izborno supstituirana s hidroksi-skupinom;
Y je prsten odabran iz skupine koja se sastoji od sljedećih prstena: piperidinila, piperazinila, pirolidinila, 1,3-ciklobutila, 1,3-ciklopentila, 1,2-ciklopropila, azetidinila, azabiciklo-oktila, morfolinila i cikloheksila, pri čemu je navedeni prsten izborno supstituiran s jednim ili više supstituenata koji su odabrani iz skupine koja se sastoji od hidroksi-skupine, (C1-3)alkilenil-OH-skupine, (C1-3)alkilenil-O-(C1-3)alkil-skupine, (C1-3)alkilenil-CONR'R''-skupine i CONR'R''-skupine, gdje su R' i R'' atom vodika ili (C1-3)alkil;
L2 je δ-veza, -(C1-3)alkilenil-skupina, NR'''-skupina, NR'''-(C1-3)alkilenil-skupina, (C1-3)alkilenil-NR'''-skupina, NR'''-(C1-3)alkilenil-NR'''-skupina ili (C1-3)alkilenil-NR'''-(C1-3)alkilenil-skupina, gdje je navedena skupina izborno supstituirana s hidroksi-skupinom, dok R''' je vodik, (C1-3)alkil, (C1-3)alkilenil-OH, (C1-3)alkilenil-O-(C1-3)alkil ili (C1-3)alkilenil-CONR'R'', pri čemu su R' i R'' atom vodika ili (C1-3)alkil;
R je δ-veza ili heterociklički, alifatski ili aromatski prsten koji ima pet članova s jednim ili više atoma dušika, koji je izborno supstituiran sa CH2OH, CH2CN, CN ili CONR'R'', pri čemu R' i R'' predstavljaju atom vodika ili (C1-3)alkil; te
B je ciklička skupina koja ima sljedeću formulu (VI):
[image]
u kojoj
G6 je CH ili N;
R2 je atom vodika ili atom halogena;
i adicijske soli s farmaceutski prihvatljivim organskim ili anorganskim kiselinama ili lužinama, enantiomeri, N-oksidi i kvaternarne amonijeve soli navedenog spoja formule (1).
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je R2 odabran iz skupine koju čine atom vodika, atom fluora, atom klora i atom broma.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da je R2 odabran iz skupine koju čine atom vodika i atom fluora.
4. Spoj prema patentnom zahtjevu 1, naznačen time, da L1 je δ-veza ili metilen-skupina (-CH2-).
5. Spoj prema patentnom zahtjevu 1, naznačen time, da L2 je δ-veza, (C1-3)alkilenil-skupina, NR'''-skupina, NR'''-(C1-3)alkilenil-skupina, (C1-3)alkilenil-NR'''-skupina, NR'''-(C1-3)alkilenil-NR'''-skupina ili (C1-3)alkilenil-NR'''-(C1-3)alkilenil-skupina, gdje je navedena skupina izborno supstituirana s jednom ili više hidroksi-skupina.
6. Spoj prema patentnom zahtjevu 5, naznačen time, da L2 je δ-veza, (C1-2)alkilenil-skupina, NR'''-skupina, NR'''-(C1-2)alkilenil-skupina, (C1-2)alkilenil-NR'''-skupina, NR'''-(C1-2)alkilenil-NR'''-skupina ili (C1-2)alkilenil-NR'''-(C1-2)alkilenil-skupina, gdje je navedena skupina izborno supstituirana s jednom hidroksi-skupinom.
7. Spoj prema patentnom zahtjevu 1, naznačen time, da R je δ-veza ili aromatski heterociklički prsten koji ima pet članova s jednim ili više atoma dušika, koji je izborno supstituiran sa CH2CN ili CN.
8. Spoj prema patentnom zahtjevu 7, naznačen time, da R je δ-veza, 1H-imidazol-4-il-skupina ili 1H-pirol-2-il-skupina, koja je izborno supstituirana sa CH2CN ili CN.
9. Spoj prema patentnom zahtjevu 1, naznačen time, da A je ciklička skupina koja ima jednu od sljedećih formula:
[image]
[image]
[image]
[image]
[image]
.
10. Spoj prema patentnom zahtjevu 1, naznačen time, da Y je prsten koji ima jednu od sljedećih formula:
[image]
[image]
[image]
[image]
[image]
[image]
.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da B je ciklička skupina koja ima jednu od sljedećih formula:
[image]
.
12. Farmaceutski pripravak, naznačen time, da obuhvaća najmanje jedan spoj formule (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 11, njegovu sol s farmaceutski prihvatljivom organskom ili anorganskom kiselinom ili s farmaceutski prihvatljivom organskom ili anorganskom lužinom, njegov enantiomer, njegovu kvaternarnu amonijevu sol ili njegov N-oksid, te
najmanje jedno inertno farmaceutski prihvatljivo pomoćno sredstvo.
13. Spoj formule (1) prema bilo kojem od prethodnih patentnih zahtjeva 1 do 11, naznačen time, da se upotrebljava u medicini.
14. Spoj formule (1) prema bilo kojem od prethodnih patentnih zahtjeva 1 do 11, naznačen time, da se upotrebljava u liječenju bakterijskih infekcija.
15. Spoj formule (1) prema bilo kojem od prethodnih patentnih zahtjeva 1 do 11, za uporabu prema patentnom zahtjevu 14, naznačen time, da se navedena bakterijska infekcija odabire iz skupine koju čine kožna infekcija, mukozna infekcija, ginekološka infekcija, infekcija respiratornog trakta (RTI), infekcija centralnog nervnog sustava (CNS), gastro-intestinalna infekcija, infekcija kostiju, kardiovaskularna infekcija, infekcija prenesena seksualnim putem ili infekcija urinarnog trakta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173550 | 2016-06-08 | ||
| EP17732775.6A EP3468975B1 (en) | 2016-06-08 | 2017-06-05 | New antibacterial compounds |
| PCT/EP2017/063600 WO2017211759A1 (en) | 2016-06-08 | 2017-06-05 | New antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200894T1 true HRP20200894T1 (hr) | 2020-09-18 |
Family
ID=56116327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200894TT HRP20200894T1 (hr) | 2016-06-08 | 2020-06-04 | Novi antibakterijski spojevi |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10640488B2 (hr) |
| EP (2) | EP3468975B1 (hr) |
| JP (2) | JP2019517545A (hr) |
| KR (2) | KR20190019084A (hr) |
| CN (2) | CN109415373A (hr) |
| AR (2) | AR108777A1 (hr) |
| AU (2) | AU2017276627A1 (hr) |
| BR (2) | BR112018075334A2 (hr) |
| CA (2) | CA3025624A1 (hr) |
| CY (1) | CY1123194T1 (hr) |
| DK (1) | DK3468975T3 (hr) |
| EA (2) | EA201892822A1 (hr) |
| ES (1) | ES2802233T3 (hr) |
| HR (1) | HRP20200894T1 (hr) |
| HU (1) | HUE049547T2 (hr) |
| IL (2) | IL263283A (hr) |
| LT (1) | LT3468975T (hr) |
| MA (1) | MA45221A (hr) |
| MD (1) | MD3468975T2 (hr) |
| ME (1) | ME03738B (hr) |
| MX (2) | MX2018015125A (hr) |
| PL (1) | PL3468975T3 (hr) |
| PT (1) | PT3468975T (hr) |
| RS (1) | RS60511B1 (hr) |
| SG (2) | SG11201810389XA (hr) |
| SI (1) | SI3468975T1 (hr) |
| WO (2) | WO2017211760A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517545A (ja) * | 2016-06-08 | 2019-06-24 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 新しい抗菌性化合物 |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| CN113698412A (zh) * | 2021-09-01 | 2021-11-26 | 临沂大学 | 一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023137007A1 (en) * | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2886570B2 (ja) | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
| MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| US5607936A (en) | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
| FR2822154B1 (fr) | 2001-03-13 | 2005-10-21 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| US6921821B2 (en) * | 2002-06-12 | 2005-07-26 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
| DE102004041163A1 (de) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| WO2006046552A1 (ja) * | 2004-10-27 | 2006-05-04 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| CA2603322C (en) | 2005-03-31 | 2014-12-16 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
| US20090131444A1 (en) * | 2005-05-24 | 2009-05-21 | Astrazeneca Ab | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity |
| MY150958A (en) * | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| WO2006137485A1 (ja) * | 2005-06-24 | 2006-12-28 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| CN101346379A (zh) * | 2005-10-21 | 2009-01-14 | 葛兰素集团有限公司 | 用作抗菌剂的周环并合的三环化合物 |
| EP2481735A1 (en) * | 2007-05-09 | 2012-08-01 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| JP5620636B2 (ja) * | 2007-11-26 | 2014-11-05 | 富山化学工業株式会社 | 新規な複素環化合物またはその塩を含有する抗菌剤 |
| EP2300477A1 (en) * | 2008-05-23 | 2011-03-30 | Glaxo Group Limited | Tricyclic nitrogen containing compounds and their use as antibacterials |
| EA018817B1 (ru) | 2008-05-23 | 2013-10-30 | Глэксо Груп Лимитед | Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств |
| TW201022279A (en) * | 2008-11-14 | 2010-06-16 | Astrazeneca Ab | Chemical compounds |
| ES2561631T3 (es) | 2009-01-15 | 2016-02-29 | Glaxo Group Limited | Compuestos de naftiridin-2(1H)-ona útiles como agentes antibacterianos |
| JP5662346B2 (ja) | 2009-01-21 | 2015-01-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 新規二環式抗生物質 |
| US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
| WO2012117421A1 (en) * | 2011-03-02 | 2012-09-07 | Orchid Research Laboratories Ltd | Histone deacetylase inhibitors |
| CA2840060A1 (en) * | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| KR20140096337A (ko) | 2011-11-08 | 2014-08-05 | 액테리온 파마슈티칼 리미티드 | ２-옥소-옥사졸리딘-３,５-디일 항생제 유도체 |
| TW201326180A (zh) | 2011-11-30 | 2013-07-01 | Actelion Pharmaceuticals Ltd | ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素 |
| CN105218501A (zh) * | 2014-07-03 | 2016-01-06 | 南京大学 | 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用 |
| EA031589B1 (ru) * | 2014-08-22 | 2019-01-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae |
| MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
| MA41169A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| JP2019517545A (ja) * | 2016-06-08 | 2019-06-24 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 新しい抗菌性化合物 |
-
2017
- 2017-06-05 JP JP2018564236A patent/JP2019517545A/ja active Pending
- 2017-06-05 US US16/307,193 patent/US10640488B2/en not_active Expired - Fee Related
- 2017-06-05 CN CN201780039687.1A patent/CN109415373A/zh active Pending
- 2017-06-05 LT LTEP17732775.6T patent/LT3468975T/lt unknown
- 2017-06-05 EP EP17732775.6A patent/EP3468975B1/en active Active
- 2017-06-05 CA CA3025624A patent/CA3025624A1/en not_active Abandoned
- 2017-06-05 MA MA045221A patent/MA45221A/fr unknown
- 2017-06-05 AU AU2017276627A patent/AU2017276627A1/en not_active Abandoned
- 2017-06-05 ME MEP-2020-112A patent/ME03738B/me unknown
- 2017-06-05 MX MX2018015125A patent/MX2018015125A/es unknown
- 2017-06-05 DK DK17732775.6T patent/DK3468975T3/da active
- 2017-06-05 EP EP17727595.5A patent/EP3468970A1/en not_active Withdrawn
- 2017-06-05 SI SI201730306T patent/SI3468975T1/sl unknown
- 2017-06-05 KR KR1020187036946A patent/KR20190019084A/ko not_active Application Discontinuation
- 2017-06-05 KR KR1020187036945A patent/KR20190019083A/ko not_active Application Discontinuation
- 2017-06-05 RS RS20200735A patent/RS60511B1/sr unknown
- 2017-06-05 EA EA201892822A patent/EA201892822A1/ru unknown
- 2017-06-05 WO PCT/EP2017/063601 patent/WO2017211760A1/en unknown
- 2017-06-05 SG SG11201810389XA patent/SG11201810389XA/en unknown
- 2017-06-05 CN CN201780042649.1A patent/CN109790157A/zh active Pending
- 2017-06-05 EA EA201892815A patent/EA201892815A1/ru unknown
- 2017-06-05 MX MX2018015126A patent/MX2018015126A/es unknown
- 2017-06-05 WO PCT/EP2017/063600 patent/WO2017211759A1/en unknown
- 2017-06-05 HU HUE17732775A patent/HUE049547T2/hu unknown
- 2017-06-05 CA CA3025270A patent/CA3025270A1/en not_active Abandoned
- 2017-06-05 PT PT177327756T patent/PT3468975T/pt unknown
- 2017-06-05 BR BR112018075334-3A patent/BR112018075334A2/pt not_active IP Right Cessation
- 2017-06-05 PL PL17732775T patent/PL3468975T3/pl unknown
- 2017-06-05 BR BR112018075297-5A patent/BR112018075297A2/pt not_active IP Right Cessation
- 2017-06-05 SG SG11201810352XA patent/SG11201810352XA/en unknown
- 2017-06-05 MD MDE20190471T patent/MD3468975T2/ro not_active IP Right Cessation
- 2017-06-05 US US16/307,410 patent/US10633366B2/en not_active Expired - Fee Related
- 2017-06-05 ES ES17732775T patent/ES2802233T3/es active Active
- 2017-06-05 JP JP2018564240A patent/JP2019517546A/ja active Pending
- 2017-06-05 AU AU2017276626A patent/AU2017276626A1/en not_active Abandoned
- 2017-06-07 AR ARP170101554A patent/AR108777A1/es unknown
- 2017-06-07 AR ARP170101555A patent/AR108778A1/es unknown
-
2018
- 2018-11-26 IL IL263283A patent/IL263283A/en unknown
- 2018-11-26 IL IL263285A patent/IL263285A/en unknown
-
2020
- 2020-06-04 HR HRP20200894TT patent/HRP20200894T1/hr unknown
- 2020-06-29 CY CY20201100597T patent/CY1123194T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200894T1 (hr) | Novi antibakterijski spojevi | |
| Göker et al. | Synthesis and potent antibacterial activity against MRSA of some novel 1, 2-disubstituted-1H-benzimidazole-N-alkylated-5-carboxamidines | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| NO20062370L (no) | Amidderivater | |
| US20130190303A1 (en) | Bridged heterocyclic compounds and methods of use | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| ES2198474T3 (es) | Compuestos heterociclicos. | |
| PT93639A (pt) | Processo para a preparacao de acidos 5-alquilquinolonocarboxilicos | |
| JP2015505301A5 (hr) | ||
| IL226579A (en) | Substances for use in respiratory viral infections | |
| HRP20171273T1 (hr) | Spoj dikarboksilne kiseline | |
| BR112020024498A2 (pt) | combinações de compostos de beta-lactam e probenecida e usos dos mesmos | |
| TW200504070A (en) | 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| US9540389B2 (en) | Antimicrobial potentiators | |
| RU2007125660A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| MXPA05010112A (es) | Derivados 8-perfluoroalquil-6, 7, 8, 9-tetrahidropirimido [1,2-a] pirimidin-4 -ona substituidos. | |
| DE3934082A1 (de) | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel | |
| RU2008110945A (ru) | N-оксиды как пролекарства производных пиперазина и пиперидина | |
| JP2019535837A (ja) | 向精神薬およびその使用 | |
| PH12020550761A1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | |
| WO2016067009A1 (en) | Compounds with activity against bacteria and mycobacteria | |
| BR112013021518A2 (pt) | uso de derivados de poliaminoisoprenil em tratamento antibiótico ou antisséptico | |
| EP1562596B1 (de) | Pyridinalykl-aminoalkyl-1h-indol derivate mit hemmender wirkung auf die 5-ht und serotonin wiederaufnahme als antidepressiva und anxiolytika | |
| EA201071014A1 (ru) | Новые 7-замещенные производные 3-карбоксиоксадиазинохинолонов, способ их получения и применение в качестве антибактериальных средств | |
| DE3522405A1 (de) | 1,8-verbrueckte 4-chinolon-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel und ihre verwendung zur herstellung von arzneimitteln |